Vascular Closure Devices Market (2026 - 2035)

Vascular Closure Devices Market Research Report: Size, Share, Trend Analysis By Device Type (Passive Closure Devices, Active Closure Devices, Suture Closure Devices, Collagen-based Closure Devices), By Procedure Type (Transvascular Procedures, Cardiac Procedures, Peripheral Procedures), By End Users (Hospitals, Ambulatory Surgical Centers, Specialty Clinics), By Distribution Channel (Direct Sales, Online Sales, Third-party Distributors) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035
ID: MRFR/HC/4249-HCR
200 Pages
Vikita Thakur, Rahul Gotadki
Last Updated: July 03, 2026
Vascular Closure Devices Market
Market Size
Forecast Period2026-2035
CAGR (2026-2035)7.05%
2025 Market SizeUSD 1.88 Billion
2035 Market SizeUSD 3.69 Billion
Key Players
Abbott
Terumo
Teleflex
Medtronic
Boston Scientific
Becton Dickinson
Trends
  • TAVR and EVAR Procedural Growth
  • Large-Bore Access Standardization
  • Outpatient and Same-Day Discharge Mandates
Opportunities
  • Fully Resorbable Closure Platforms
  • Large-Bore Systems Tied to Structural Heart Expansion
  • Emerging Market Cath Lab Build-Out
Request Free Sample

Vascular Closure Devices Market Summary

The Vascular Closure Devices Market size was valued at USD 1.88 Billion in 2025, and the market is projected to grow from USD 2.00 Billion in 2026 to USD 3.69 Billion by 2035, registering a CAGR of 7.05% during the forecast period 2026–2035. That trajectory is anchored less to a single catalyst than to a convergence of two: the FDA's continued clearance pace for large-bore access closure platforms supporting transcatheter aortic valve replacement (TAVR), and CMS outpatient payment expansions that have pulled a meaningful share of elective catheterization volume into ambulatory settings. Hospitals and cath labs alike are responding by standardizing device-based closure over manual compression, particularly where access sites now routinely approach 22–25 Fr.

Below the headline number is a real technology shift. Active approximator systems and bioabsorbable collagen plugs are gradually supplanting legacy manual and figure-eight suture closure, compressing ambulation time from hours to less than sixty minutes. Industry capital flows mirror the pivot – financing rounds for closure devices and corporate R&D investments are said to have surpassed USD 400 million throughout 2023-2025, with manufacturers racing to reduce deployment time and eliminate operator-dependent variability from large-bore cases.

 

North America accounts for the lion’s share of the Vascular Closure Devices Market, due to its extensive cath lab infrastructure and favorable reimbursement. Asia-Pacific is the fastest-expanding region, with China and India scaling up interventional cardiology capacity. Europe is the second largest contributor after North America, driven by the launch of products compliant with MDR and growth in the structural heart program. As the global expansion of large-bore procedures continues, the gravity center for vascular closure, both competitive and clinical, is poised to shift from the edges of the operating room to the heart of the procedural protocol.

 

Key Report Takeaways

• By Technology

  • Active approximators led the Vascular Closure Devices Market with a 50.6% revenue share in 2025, reflecting clinician preference for mechanical, suture-mediated closure in higher-volume cath labs.
  • Passive approximator (collagen plug) systems are forecast to expand at a 7.5% CAGR through 2035 as bioabsorbable formulations gain traction in lower-acuity cases.
  • Collagen-based materials accounted for an estimated USD 0.88 billion of the Vascular Closure Devices Market in 2025.

• By Sector

  • Interventional cardiology represented 35.2% of procedure-linked demand in 2025, the largest single procedural category.
  • Neurovascular procedures are projected to post the fastest segment CAGR, at 9.9% through 2035, as endovascular stroke intervention volumes rise.
  • Femoral access sites of 8 Fr or smaller held a 56.3% share in 2025, though large-bore femoral access (≥12 Fr) is the quickest-growing access category.

• By Geography

  • North America retained the largest regional position in the Vascular Closure Devices Market in 2025, supported by dense TAVR and EVAR program density.
  • Asia-Pacific is forecast to grow at a 9.6% CAGR through 2035, the fastest of any region.
  • Hospitals captured a 51.0% end-user share of the Vascular Closure Devices Market in 2025.

Market Size and Forecast (2021–2035)

Figures below are based on a base-year (2025) calibration of USD 1.88 billion, projected forward at a 7.05% CAGR, and reconciled against historical procedural-volume data for 2021-2024. The Vascular Closure Devices Market will see a minor slowdown during 2021-2023 because of the postponement of elective procedures amid the pandemic, with a gradual recovery kicking in from 2024 onwards.

Vascular Closure Devices Market Size and Forecast
Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

Driver Impact Analysis

Driver ~% Impact on CAGR Geographic Relevance Impact Timeline
TAVR/EVAR procedural volume growth ~1.8% Global Long-term
Large-bore access device adoption (up to 25 Fr) ~1.4% North America, Europe Medium-term
Same-day discharge/outpatient mandates ~1.1% North America Short-term
Bioabsorbable closure material innovation ~0.9% Global Medium-term
Aging population & rising PAD prevalence ~1.0% Asia-Pacific, Europe Long-term
Reimbursement expansion for ambulatory procedures ~0.7% North America Short-term
Femoral access procedural standardization ~0.5% Global Medium-term

 

TAVR and EVAR Procedural Growth

Transcatheter aortic valve replacement volumes in the United States alone have climbed past an estimated 150,000 annual procedures, and each case routinely requires large-bore closure. As CMS coverage criteria broaden into lower-risk patient cohorts, closure-device pull-through scales proportionally with procedural count rather than with hospital count, concentrating demand growth in high-volume centers [1].

Large-Bore Access Standardization

Device clearances supporting access sites up to 25 Fr have expanded materially since 2022, and several large academic centers now report device-based closure rates above 85% for structural heart cases — up from roughly 60% five years prior [2].

Outpatient and Same-Day Discharge Mandates

CMS removal of select cardiac catheterization procedures from the inpatient-only list has pushed same-day discharge protocols into mainstream use, and predictable hemostasis is a prerequisite for early ambulation pathways that hospitals depend on to manage bed capacity [3].

Restraints Impact Analysis

As with drivers, restraint impact figures are directional approximations of downward pressure on CAGR and are not strictly additive.

Restraint ~% Impact on CAGR Geographic Relevance Impact Timeline
High device cost vs. manual compression ~1.2% Emerging markets Short-term
Vascular complication risk (pseudoaneurysm, infection) ~0.8% Global Medium-term
Reimbursement variability across geographies ~0.6% Asia-Pacific, Latin America Medium-term
Operator training and learning curve ~0.5% Global Short-term
Stringent regulatory pathways for new materials ~0.4% Europe (MDR) Long-term

 

Cost Sensitivity in Price-Constrained Systems

A single active approximator device can carry a per-unit cost several multiples above manual compression supplies, a gap that public hospital systems in price-sensitive markets are slow to absorb without bundled procedural reimbursement [8].

Regulatory Friction Under EU MDR

Post-MDR conformity reassessment has lengthened average time-to-market for new collagen and polymer-based closure formulations in the EU by an estimated 9–14 months relative to the prior medical device directive regime, slowing the pace of next-generation product launches in the region [12].

Vascular Closure Devices Market Opportunities

Fully Resorbable Closure Platforms

Manufacturers investing in fully bioabsorbable plug and approximator chemistries stand to capture share from clinicians wary of permanent intravascular hardware, particularly in younger structural heart patients who may require repeat access.

Large-Bore Systems Tied to Structural Heart Expansion

As TAVR indications broaden, closure platforms purpose-built for 22–25 Fr sheaths represent a high-margin, high-growth adjacency tightly coupled to structural heart program build-out.

Emerging Market Cath Lab Build-Out

India and Southeast Asia are adding catheterization lab capacity faster than device-based closure penetration is rising, leaving a meaningful conversion opportunity as manual compression remains the default in many tier-2 hospitals.

Procedural Data and Outcomes Registries

Device makers bundling closure hardware with cloud-based outcomes tracking and registry participation are opening new service-revenue lines beyond the device sale itself, mirroring data-monetization models seen elsewhere in interventional cardiology.

Radial-Specific Compression Innovation

As operators migrate select procedures from femoral to radial access, compression-band design tailored to radial hemostasis addresses a procedural segment that traditional femoral closure platforms do not serve.

Vascular Closure Devices Market Future Outlook

AI-Assisted Procedural Planning

Predictive software that recommends closure device type based on access-site anatomy and patient risk profile is moving from pilot programs into commercial rollout, with early adopters reporting fewer access-site complications.

Platform Economics

Manufacturers are increasingly bundling closure devices across multiple access sizes into single procedural kits, shifting competitive emphasis from individual device performance toward portfolio breadth and hospital system contracting.

Outpatient and Ambulatory Economics

As same-day discharge protocols mature, hospital procurement decisions are weighing closure-device reliability and ambulation-time predictability more heavily than unit price, reshaping vendor selection criteria.

ESG and Supply Chain Reporting

Device manufacturers are beginning to disclose sterilization energy use and packaging waste metrics in response to investor and hospital-system ESG procurement criteria, a trend expected to influence vendor scorecards through the back half of the forecast period.

Vascular Closure Devices Market Segmentation

By Product Type

Segment Key Metric Primary Demand Driver
Active Approximators 50.6% share (2025) Mechanical suture-mediated closure preference
Passive Approximators 7.5% CAGR (2026–2035) Bioabsorbable collagen plug adoption

 

Active approximators remain the clinical default in high-volume cath labs because of consistent deployment time, while passive approximator systems are gaining ground as collagen-based formulations improve reabsorption profiles.

By Material Composition and Mode of Access

Segment Key Metric Primary Demand Driver
Collagen-Based USD 0.88 Billion (2025) Established clinical track record
Suture/Filament-Based 9.3% CAGR (2026–2035) Reusability across repeat-access patients
Femoral Access ≤8 Fr 56.3% share (2025) Standard diagnostic and low-acuity procedures
Large-Bore Femoral ≥12 Fr 7.1% CAGR (2026–2035) TAVR/EVAR case volume growth

 

Collagen-based systems retain the largest material share given decades of clinical familiarity. However, suture and filament-based platforms are growing fastest as operators value their compatibility with repeat femoral access.

By Procedure Type

Segment Key Metric Primary Demand Driver
Interventional Cardiology 35.2% share (2025) High procedural volume base
Neurovascular 9.9% CAGR (2026–2035) Endovascular stroke intervention growth
Peripheral Vascular USD 0.34 Billion (2025) PAD prevalence increases
Structural Heart/TAVR 8.4% CAGR (2026–2035) Large-bore indication expansion

 

Interventional cardiology remains the anchor procedural category, but neurovascular procedures are scaling fastest as stroke-center networks expand mechanical thrombectomy capacity.

By End User

Segment Key Metric Primary Demand Driver
Hospitals 51.0% share (2025) Comprehensive procedural capability
Catheterization Labs / ASCs 7.8% CAGR (2026–2035) Shift toward ambulatory procedural settings
Outpatient Vascular Centers USD 0.21 Billion (2025) Same-day discharge protocol adoption

 

Hospitals continue to handle the bulk of complex large-bore cases. Still, standalone catheterization labs and ambulatory surgical centers are absorbing a growing share of lower-acuity diagnostic and peripheral procedures.

Regional Market Share Analysis

Region Key Metric (2025) Primary Investment Themes
North America 37.4% market share Large-bore platforms, outpatient cath labs
Europe USD 0.51 Billion MDR-compliant launches, structural heart growth
Asia-Pacific 9.6% CAGR (2026–2035) Cath lab infrastructure build-out, China/India volume growth
South America 6.0% market share Private hospital network expansion
Middle East & Africa USD 0.11 Billion Tertiary cardiac center investment
**Total** **USD 1.88 Billion (2025)** —

 

North America

Country Key Metric (Share of Region) Key Driver
US 84% TAVR/EVAR program density
Canada 10% Provincial reimbursement expansion
Mexico 6% Private hospital cath lab growth

 

North America's lead rests on procedural depth rather than procedural count alone: high-volume academic centers concentrate large-bore case mix and have effectively normalized device-based closure as standard of care, a pattern reinforced by CMS site-of-service payment changes.

Europe

Country Key Metric (Share of Region) Key Driver
Germany 24% High TAVR center density
UK 18% NHS elective recovery programs
France 14% Structural heart reimbursement reform
Italy 11% Cath lab modernization
Spain 9% Public hospital procurement cycles
Nordic Countries 8% Early bioabsorbable adoption
Russia 7% Tertiary center expansion
Rest of Europe 9% Gradual device-based closure conversion

 

Germany's scale advantage stems from its dense network of TAVR-capable centers, while UK volumes are recovering unevenly as NHS trusts work through elective procedure backlogs accumulated over prior years.

Asia-Pacific

Country Key Metric Key Driver
China 32% share of region Domestic device manufacturing scale-up
India 11.2% CAGR (2026–2035) Cath lab capacity expansion
Japan 22% share of region Aging population, PMDA approval pace
South Korea 12% share of region Reimbursement parity with Western devices
ASEAN 9% share of region Private hospital network growth
Rest of Asia-Pacific 8% share of region Early-stage interventional cardiology buildout

 

China's domestic manufacturers are narrowing the technology gap with multinational players. At the same time, India's growth is driven primarily by new cath lab installations outpacing the current rate of device-based closure adoption.

South America

Country Key Metric (Share of Region) Key Driver
Brazil 58% Private hospital network scale
Argentina 24% Reimbursement policy reform
Rest of South America 18% Gradual cath lab modernization

 

Brazil's private hospital networks have led regional adoption, with public-sector uptake lagging due to procurement cycle constraints.

Middle East & Africa

Country Key Metric (Share of Region) Key Driver
Saudi Arabia 27% Vision 2030 healthcare infrastructure investment
UAE 23% Medical tourism-linked tertiary centers
South Africa 19% Private hospital group expansion
Egypt 14% Cath lab capacity growth
Rest of MEA 17% Early-stage market development

 

Saudi Arabia's growth is closely tied to national healthcare infrastructure investment programs that are funding new tertiary cardiac centers across the kingdom.

Vascular Closure Devices Market By Region, 2025-2035

Competitive Benchmarking

The Vascular Closure Devices Market is moderately concentrated, with the top-5 companies projected to hold a combined revenue share in the region of 55-65% and an approximate HHI in the moderately concentrated band. No vendor is a clear leader, and competitive differentiation is driven by speed of deployment, big bore compatibility and bioabsorbable material innovation.

Company Est. Revenue Share Range Key Offerings for the Vascular Closure Devices Market Strategic Positioning
Abbott ~14–17% Active approximator and suture-mediated closure systems Broad cath lab portfolio integration
Terumo ~11–14% Collagen-based and radial compression devices Strength in Asia-Pacific distribution
Teleflex ~10–13% Collagen plug and large-bore closure platforms Acquisitive growth via niche device makers
Medtronic ~9–12% Vascular closure adjacent to the structural heart portfolio Bundled TAVR procedural kits
Boston Scientific ~8–11% Peripheral and femoral access closure devices Peripheral vascular franchise leverage
Becton Dickinson ~6–9% Suture-based and access-site management devices Hospital procurement scale
Cordis ~5–8% Femoral closure systems Legacy interventional cardiology base
Merit Medical Systems ~4–7% Compression and closure accessory devices Cost-competitive positioning
Haemonetics (Cardiva) ~3–6% Mechanical, non-implant closure devices Differentiated reversible-mechanism platform
InSeal Medical ~2–4% Large-bore vascular closure systems Structural heart-focused niche entrant

 

Recent News & Developments

 

 

  • Terumo (January 2024): Announced a distribution partnership to expand radial compression band availability across Southeast Asia [15].

 

  • Boston Scientific (November 2023): Disclosed peripheral vascular portfolio investment, including closure-adjacent access management tools [17].

 

  • EU MDR Notified Bodies (2024): Issued updated guidance affecting conformity reassessment timelines for collagen-based implantable closure materials [12].
  • CMS (2023): Finalized outpatient payment rule changes affecting site-of-service economics for select catheterization procedures [3].

Vascular Closure Devices Market Report Scope

Parameter Detail
Market Scope Vascular closure devices across product type, material composition, access mode, procedure, end user, and geography
Study Period 2021–2035
CAGR 7.05% (2026–2035)
Market Size Checkpoints 2025: USD 1.88 B; 2026: USD 2.00 B; 2031: USD 2.81 B; 2035: USD 3.69 B
Fastest Growing Segments Neurovascular procedures; Asia-Pacific region; large-bore femoral access
Companies Profiled 10 (Section 10)
Valuation Currency USD Billion

 

FAQs

What should hospital procurement teams weigh most when comparing closure-device vendors?
Deployment consistency across operators matters more than unit price alone. Vendors with documented complication-rate data across diverse access sizes typically win multi-year contracts [9].
How do bioabsorbable and permanent-implant closure devices differ in practice?
Bioabsorbable devices dissolve over weeks, reducing concerns about repeat-access interference. Permanent implants offer faster deployment but carry long-term foreign-material considerations [4].
Is device-based closure replacing manual compression entirely?
No. Manual compression remains common for low-acuity diagnostic cases, especially in cost-constrained settings. Device-based closure concentrates in large-bore and high-volume procedural environments [8].
What regulatory nuance affects new closure-material launches in Europe?
EU MDR conformity reassessment has extended approval timelines for implantable materials. Manufacturers now budget longer commercialization windows for collagen and polymer-based products [12].
Are there integration challenges when adopting AI-assisted closure-selection tools?
Yes — integration with existing electronic health record and cath lab imaging systems remains uneven. Hospitals piloting these tools report workflow friction during the first implementation phase.
How does radial access growth affect closure-device demand?
Radial procedures use compression bands rather than implantable closure devices, so volume migration toward radial access shifts revenue toward a different product category entirely [7].
What competitive dynamic is reshaping smaller closure-device manufacturers?
Niche players like InSeal Medical are being acquired or partnered with by larger vendors seeking large-bore portfolio gaps, consolidating innovation under established distribution networks [18].
What is the current size of the vascular closure devices market?
The vascular closure devices market reached USD 1.88 billion in 2025 and is projected to reach USD 3.69 billion by 2035.
What is the CAGR of the vascular closure devices market?
The vascular closure devices market is projected to grow at a CAGR of 7.05% during the forecast period 2026–2035.
Which region leads the vascular closure devices market?
North America holds the largest share at 37.4%, while Asia-Pacific is the fastest-growing region at 9.6% CAGR.
Author
Author
Author Profile
Vikita Thakur LinkedIn
Senior Research Analyst
She holds an experience of about 5+ years in market research and business consulting projects for sectors such as life sciences, medical devices, and healthcare IT. She possesses a robust background in data analysis, market estimation, competitive intelligence, pipeline analysis market trend identification, and consumer behavior insights. Her expertise lies in technical Sales support, client interaction and project management, designing and implementing market research studies, conducting competitive analysis, and synthesizing complex data into actionable recommendations that drive business growth.
Co-Author
Co-Author Profile
Rahul Gotadki LinkedIn
Research Manager
He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.
Get In Touch

Research Approach

 

Secondary Research

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed cardiology and vascular surgery journals, interventional procedure registries, and authoritative cardiovascular health organizations. Key sources included the US Food & Drug Administration (FDA) Center for Devices and Radiological Health, European Medicines Agency (EMA), American College of Cardiology (ACC), Society for Cardiac Angiography and Interventions (SCAI), European Society of Cardiology (ESC), Society for Vascular Surgery (SVS), American Heart Association (AHA), National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI), National Center for Biotechnology Information (NCBI/PubMed), CDC National Center for Health Statistics, World Health Organization (WHO) Global Health Observatory cardiovascular disease database, OECD Health Statistics, and national cath lab registry data from key markets.

Interventional cardiology procedure statistics (PCI, peripheral angiography, cardiac catheterization), regulatory 510(k) and PMA approval data, clinical safety and efficacy studies, cardiovascular disease epidemiology trends, and competitive landscape analysis for passive approximators, active clips/sutures, collagen plugs, and extravascular closure technologies were gathered using these sources.

 

Primary Research

Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. The supply-side sources consisted of CEOs, VPs of Research & Development, regulatory affairs heads, and commercial directors from vascular closure device manufacturers, interventional cardiology divisions of key medical device companies, and component suppliers. Interventional cardiologists, vascular surgeons, cath lab directors, electrophysiologists, and procurement managers from hospitals, ambulatory surgical centers (ASCs), and specialty cardiovascular clinics comprised demand-side sources. Primary research has confirmed the product pipeline timelines for next-generation bioabsorbable and extravascular closure devices, validated market segmentation across passive, active, suture-based, and collagen-based device categories, and gathered insights on clinical adoption patterns in diagnostic angiography versus interventional procedures, pricing strategies across hospital versus ASC settings, and reimbursement dynamics for vascular access site management.

Primary Respondent Breakdown:

By Designation: C-level Primaries (38%), Director Level (32%), Others (30%)

By Region: North America (38%), Europe (30%), Asia-Pacific (25%), Rest of World (7%)

 

Market Size Estimation

Revenue mapping and procedural volume analysis were implemented to determine global market valuation. The methodology comprised the following:

Identification of 35+ key manufacturers in North America, Europe, Asia-Pacific, and Latin America who specialize in passive approximators, active suture systems, mechanical clips, collagen-based sealants, and extravascular closure technologies

Product mapping for suture-based systems, collagen-based/biosealant categories, active closure devices, and passive closure devices

Distinction between diagnostic catheterization and interventional procedure utilization rates, as well as an examination of reported and modeled annual revenues that are specific to vascular access closure portfolios

Manufacturers that account for 75-80% of the global market share in 2024 are included in the coverage.

Extrapolation is employed to derive segment-specific valuations by device type, procedure type, and end-user setting by utilizing bottom-up (procedure volume × ASP by country, segmented by cardiac catheterization, PCI, peripheral angiography, and EP procedures) and top-down (manufacturer revenue validation across major device categories) approaches respectively.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

Customer Stories

Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.